A similar decrease in COVID-19 patients was observed for CCL13/MCP-4 (89.1 ± 9.0 vs. 155.9 ± 21.5 pg/mL, p = 0.01) and CCL22/MDC (523.9 ± 55.0 vs. 914.9 ± 109.4 pg/mL, p = 0.007). This evidence concerns the gene CCL13 and COVID-19.